
FDA clears accelerated protocol for BrainsWay Deep TMS in depression
BrainsWay (Nasdaq:BWAY) today announced the FDA granted expanded clearance for its Deep Transcranial Magnetic Stimulation system to include an accelerated treatment protocol for major depressive disorder and patients with comorbid anxiety symptoms.








